|
|
Article: Scar management has huge growth potential.(MERCHANDISING/O-T-C HEALTH CARE)(Statistical table)
- Article from:
- Chain Drug Review
- Article date:
- August 3, 2009
CopyrightCOPYRIGHT 2009 Racher Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Scar treatments generate more than $50 million in annual sales. Drug chains typically have a 40% to 50% margin on the products, making the category highly profitable.
The segment also plays an important role in the chains' strategy of providing a comprehensive health care product selection. Chain drug retailers carry an array of scar products unavailable elsewhere, helping them differentiate themselves from other trade classes. Products available at drug chains include Scarguard Labs LLC's Scarguard MD, Mederma from Merz Pharmaceuticals LLC and Bio-Oil from Pacific World Corp.
The scar category has a huge potential for growth. Hundreds of ...